Research programme: radiolabelled antagonistic peptides - OctreoPharmAlternative Names: 177LU-OPS 201; OPS 201; SOMther
Latest Information Update: 11 Nov 2015
At a glance
- Originator OctreoPharm Sciences
- Class Peptides; Radiopharmaceuticals
- Mechanism of Action Somatostatin receptor 2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuroendocrine tumours